BTK and myeloid sarcoma: The development of CNS-penetrant inhibitors of BTK has raised the exciting prospect that such treatment could impact not only peripheral immune cells involved in MS relapses, but also elements of CNS-compartmentalized inflammation thought to be involved in non-relapsing progressive disease [7, 22, 35, 38].